Effect of Oral Nirmatrelvir on Long COVID Symptoms: 4 Cases and Rationale for Systematic Studies

BACKGROUND: Efforts to understand the impact of SARS-CoV-2 variants, vaccine status, and treatment on the development and persistence of Long COVID have intensified. METHODS: We report 4 sequential cases from a post-COVID cohort study demonstrating variability in outcomes following differentially ti...

Descripción completa

Detalles Bibliográficos
Autores principales: Peluso, Michael J., Anglin, Khamal, Durstenfeld, Matthew S., Martin, Jeffrey N., Kelly, J. Daniel, Hsue, Priscilla Y., Henrich, Timothy J., Deeks, Steven G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pathogens and Immunity 2022
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254867/
https://www.ncbi.nlm.nih.gov/pubmed/35800257
http://dx.doi.org/10.20411/pai.v7i1.518
Descripción
Sumario:BACKGROUND: Efforts to understand the impact of SARS-CoV-2 variants, vaccine status, and treatment on the development and persistence of Long COVID have intensified. METHODS: We report 4 sequential cases from a post-COVID cohort study demonstrating variability in outcomes following differentially timed nirmatrelvir therapy, received as part of clinical care. RESULTS: In the first case, the participant experienced symptomatic rebound and developed Long COVID despite early initiation of antiviral therapy. In the next 2 cases, participants reported improvement in persistent COVID symptoms when nirmatrelvir was taken 25 and 60 days following initial symptom onset. In the final case, an individual with presumed Long COVID for 2 years reported substantial improvement in chronic symptoms when taking nirmatrelvir following SARS-CoV-2 re-infection. CONCLUSIONS: These anecdotes suggest that systematic study of antiviral therapy for Long COVID is warranted.

Ejemplares similares